Analysts predict that ADMA Biologics Inc (NASDAQ:ADMA) will post ($0.26) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for ADMA Biologics’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.13). ADMA Biologics posted earnings per share of ($0.35) in the same quarter last year, which would indicate a positive year over year growth rate of 25.7%. The company is scheduled to issue its next quarterly earnings results on Friday, August 9th.
According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($1.04) per share for the current financial year, with EPS estimates ranging from ($1.34) to ($0.79). For the next fiscal year, analysts forecast that the business will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.94) to ($0.03). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.01. The business had revenue of $3.53 million during the quarter, compared to analyst estimates of $2.96 million. ADMA Biologics had a negative return on equity of 210.69% and a negative net margin of 370.27%.
Shares of NASDAQ:ADMA traded down $0.07 during trading on Friday, hitting $3.48. The company had a trading volume of 447,937 shares, compared to its average volume of 554,047. The company has a market cap of $200.45 million, a PE ratio of -2.40 and a beta of 2.71. ADMA Biologics has a one year low of $2.08 and a one year high of $6.96. The stock has a fifty day moving average price of $3.77. The company has a debt-to-equity ratio of 5.70, a quick ratio of 2.39 and a current ratio of 4.60.
In other ADMA Biologics news, insider Adam S. Grossman purchased 30,000 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was purchased at an average cost of $4.00 per share, with a total value of $120,000.00. Following the purchase, the insider now owns 37,527 shares of the company’s stock, valued at $150,108. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 4,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were acquired at an average cost of $4.00 per share, with a total value of $16,000,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,064,500 shares of company stock valued at $16,258,000 over the last three months. 15.20% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of ADMA. United Services Automobile Association bought a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $27,000. Dimensional Fund Advisors LP bought a new stake in ADMA Biologics during the 4th quarter valued at $34,000. Raymond James & Associates raised its position in ADMA Biologics by 65.2% during the 4th quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 10,610 shares in the last quarter. Geode Capital Management LLC raised its position in ADMA Biologics by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 34,818 shares in the last quarter. Finally, BlackRock Inc. raised its position in ADMA Biologics by 0.5% during the 4th quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock valued at $2,305,000 after purchasing an additional 4,577 shares in the last quarter. 38.70% of the stock is owned by hedge funds and other institutional investors.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Recommended Story: Portfolio Manager
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.